Weather Alert(1)!
"Winter Storm Warning" ...Winter Storm Warning in effect until 7 am EST Monday... The National Weather Service in New York has issued a Winter Storm Warning for heavy snow...which is in effect until 7 am EST Monday. The Winter Weather Advisory is no longer in effect. * Locations...much of southeast Connecticut...and central and eastern Long Island. * Hazard types...snow...briefly mixing with or changing to freezing rain across Long Island this evening. * Accumulations...snow accumulation of 4 to 7 inches. Ice accumulation of a glaze to a tenth of an inch of ice in Suffolk County. * quarter to one half mile at times. * Temperatures...upper 20s. * Timing...snow will be moderate to locally heavy at times into this evening. * Impacts...hazardous travel due to snow covered surfaces. * Winds...west 5 to 10 mph. Precautionary/preparedness actions... A Winter Storm Warning for heavy snow means severe winter weather conditions are expected or occurring. Significant amounts of snow are forecast that will make travel dangerous. Only travel in an emergency. If you must travel...keep an extra and water in your vehicle in case of an emergency. -- Sunday Mar.01 15,11:48 PM Weather  |  LIRR  |  Traffic  |  Traffic Cams |  Weather News


Risperdal Gynecomastia Lawsuits Website Launched by The Rottenstein Law Group LLP

Press Releases

The Firm represents Risperdal lawsuit clients in claims that allege the antipsychotic medication caused men and boys to develop gynecomastia..

Rockville Centre, NY - June 24th, 2014 - The Rottenstein Law Group LLP, a national law firm that specializes in personal injury cases filed by plaintiffs with claims of harm stemming from dangerous drugs and defective medical devices, announces the launch of a new website dedicated exclusively to helping men who have been injured by the atypical antipsychotic drug Risperdal.

The firm has launched in response to the rapidly growing number of lawsuits filed by men who allege that Risperdal has caused a condition known as gynecomastia, which is characterized by the abnormal growth of breast tissue. Many male patients take Risperdal as a treatment for schizophrenia and bipolar disorder, but were unaware that the drug was associated with this adverse side effect. Currently, there is a mass tort litigation underway in Pennsylvania in the Philadelphia Court of Common Pleas (Risperdal Litigation, Case Number 100300296), which has grown to include over 400 lawsuits.

“We want to get the word out about the dangers of Risperdal, and at the same time, give people the opportunity to explore their legal options if they feel they have suffered an injury caused by the drug,” said Rochelle Rottenstein, principal of the Rottenstein Law Group. “Our goal is to make the process as easy as possible, and the lawyers at our firm have the knowledge and the experience to make that happen.”

Anyone wanting more information about Risperdal and gynecomastia should visit the site, where all the important topics are explained in clear, easy to understand language. Representatives are standing by to answer questions, and there is even a confidential, no-cost claim evaluation form that can be filled out to see if grounds exist to sue the manufacturer of the drug for compensation for medical costs and other damages.

About The Rottenstein Law Group LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

For More Information, Please Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road, Suite 226W
Rockville Centre, NY 11570
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)

comments powered by Disqus

Join Our Weekly Newsletter

Sign up for a free weekly newsletter covering things to do, hottest local headlines, and everything Long Island! Read more here or enter your email to signup.

     Newsletter Archive
Advertise With Us
Open Feedback Dialog